These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32017973)

  • 1. Comparative hepatitis C genotype 1-3 viral load kinetics in response to directly-acting antiviral therapy.
    May S; Kurmoo F; Iliffe M; David J; Patel A; Wiselka M; Stephenson I; Delahooke T; Lai FY; Dustan S; Tang JW
    J Infect; 2020 May; 80(5):578-606. PubMed ID: 32017973
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
    Medeiros-Filho JE; de Carvalho Mello IM; Pinho JR; Neumann AU; de Mello Malta F; da Silva LC; Carrilho FJ
    World J Gastroenterol; 2006 Dec; 12(45):7271-7. PubMed ID: 17143940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    Song BC
    Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319
    [No Abstract]   [Full Text] [Related]  

  • 6. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Berzsenyi MD; Roberts SK
    J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
    [No Abstract]   [Full Text] [Related]  

  • 7. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Salmerón J; De Rueda PM; Ruiz-Extremera A; Casado J; Huertas C; Bernal Mdel C; Rodríguez L; Palacios A
    Dig Dis Sci; 2006 May; 51(5):960-7. PubMed ID: 16758308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    Spooner LM; Abraham GM
    Am J Health Syst Pharm; 2017 Apr; 74(8):555. PubMed ID: 28389452
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load.
    Izumi N; Asahina Y; Kurosaki M; Uchihara M; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Hamano K; Itakura J; Miyake S
    Intervirology; 2004; 47(2):102-7. PubMed ID: 15192274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2008 Aug; 48(2):692-3; author reply 693-4. PubMed ID: 18666250
    [No Abstract]   [Full Text] [Related]  

  • 11. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutagenic effects of ribavirin in vivo.
    Perelson AS; Ribeiro RM
    J Hepatol; 2005 Oct; 43(4):553-5. PubMed ID: 16099528
    [No Abstract]   [Full Text] [Related]  

  • 14. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
    Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
    J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 19. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.